StockWatch
·
JUBILANT PHARMOVA · Q2 FY-2027 · PREVIEW

Radiopharma Scaling Into Margin Headwinds—Execution Risk on SPECT Recovery

Revenue tracking ahead of plan, but Q2 will test whether capacity ramps offset near-term EBITDA compression. Markets priced for a strong H2 recovery; the Street is watching for breakeven on Montreal and Spokane.

Q2 FY27 resultsJUBLPHARMAJubilant Pharmova Ltd09 Nov 2026 · 3 min read

The Setup

Jubilant Pharmova enters Q2 FY27 with revenue momentum intact—Q1 delivered ₹2,229 Cr (+17% YoY) against backdrop of industry growth of ~12–13%. But the print masks a profitability miss: net profit crashed 45% YoY to ₹56 Cr, driven by EBITDA margin compression to 10.4% as high-margin radiopharmaceutical products remained unavailable through Q1. Management's critical bet: that commercial batch production at the Montreal CMO (begun in Q1) will release inventory and unlock 300–400 bps of margin recovery by H2 FY27. Q2 will show whether that inflection is materializing or slipping further.

Revenue expectation

~₹2,350 Cr

Implies ~5–6% QoQ, ~13% YoY on-plan for FY27 13.2% growth guide

EBITDA margin

14–15%

Still compressed vs FY26 Q2's 16.4%; SPECT recovery unlikely until H2

PAT run-rate

₹80–100 Cr

Recovery depends on both margin expansion and tax normalization post-GST notices

FY27 guidance

On track

Consistent with 13.2% revenue, 19.9% profit growth assumptions; H2 inflection critical

What a strong print looks like: Revenue above ₹2,350 Cr; EBITDA margin recovery toward 15%+ (signaling SPECT batch releases are real and capacity utilization at Montreal/Spokane is picking up); management commentary that validates H2 margin inflection thesis. What a weak print looks like: Revenue below ₹2,300 Cr; EBITDA margins remain flat or tick lower; management delays SPECT batch revenue recognition or cites further facility headwinds, raising H2 recovery risk.

On Track?

Yes, in revenue terms. Q1 YoY growth of 17% outpaced FY27 guidance of 13.2%, and the Street models continued double-digit quarterly growth through the year. But profitability is materially behind—Q1 PAT decline of 45% is a red flag if Q2 doesn't show visible margin inflection. Management's public guidance explicitly frames H2 as the recovery period (EBITDA margins start to expand from H2 FY27 onwards), which means Q2 is still a transition quarter. If margin pressure persists into Q2, Street confidence in the H2 inflection will erode quickly.

Since Last Quarter

Key Filings & Corporate Actions
  • 1 · ₹800 Cr NCD Issuance (Nov 5, Oct 12 approved)

    Board approved and allotted 80,000 unsecured, rated, listed NCDs at ₹1,00,000 face value. Signals capex intensity for radiopharma scale-up and debt-funded growth. Also aligns with stated goal of zero net debt by FY30—refinancing at a lower rate or strategic debt management for growth capex. No immediate dilution risk, but signals management's bullish capex cycle.

  • 2 · CAD 94.5M Radiopharma Investment (Oct 8)

    Announced major capex to double RUBY-FILL® production capacity at the radiopharma business—high-margin product expected to drive Q2+ growth and margin recovery. Timing is deliberate: capacity added now, revenue recognition in H2 as Montreal batches release. Key milestone to watch on result day.

  • 3 · Spokane Facility VAI Classification (Sep 11)

    Jubilant HollisterStier's Spokane CMO facility classified as Voluntary Action Indicated (VAI) by USFDA—a regulatory risk signal. However, facility has already received USFDA approval for Line 3 commercial manufacturing (Aug 23), so VAI is not a block. Monitor for impact on North American batch releases and CMO margins in future quarters.

  • 4 · GST Show-Cause Notices (Sep 1, Aug 28)

    Main entity received ₹87.31 Cr notice (₹33.58 Cr GST + interest/penalties); wholly-owned subsidiary Jubilant Generics received ₹105.5 Cr notice. Both are show-cause stage—not final demand. However, if upheld or partially upheld, could impact FY27 tax provision and PAT. No immediate cash outflow, but risk disclosure will feature in result commentary. Investors will probe management's legal position and probability of resolution.

  • 5 · Trading Window Closure (Sep 29)

    Standard pre-result insider trading blackout period commenced Sep 29, effective until 48 hours post-result declaration. No material insider activity flagged; routine compliance.

Summary: The NCD raise and RUBY-FILL capex amplify management's commitment to radiopharma scale. The Spokane VAI is a monitoring point but not a blocker. GST notices are a tail risk but unresolved; they shadow near-term sentiment but won't derail the narrative if operational performance is solid.

What to Watch on Result Day

  • 1 · EBITDA Margin Trajectory

    Is Q2 margin stabilizing or improving vs Q1's 10.4%? Management flagged H2 as the recovery inflection. If Q2 margin remains flat or ticks lower, H2 credibility takes a hit. Target watch: any sign of margin recovery toward 14–15% range is validation; flat or lower is a miss.

  • 2 · SPECT Batch Revenue Recognition

    When do Montreal SPECT batches hit the P&L? Management flagged Q1 production; commercial batch releases in Q2 would show up as revenue and margin contribution. If revenue is deferred or batch yields are below forecast, the H2 recovery thesis gets pushed back.

  • 3 · Spokane CMO Utilization & Ramp

    Any update on North American batch volume, pending customer contracts, or Line 3 commercialization pace? Spokane is a key growth driver; any slowdown in ramp would signal execution risk.

  • 4 · GST Notice Resolution Status

    Will management disclose strategy, timeline, or probability-weighted provision for the ₹87.31 Cr and ₹105.5 Cr GST notices? Street will parse legal commentary closely for downside tail-risk quantification.

  • 5 · FY27 Guidance Reaffirmation

    Does management reaffirm or revise the 13.2% revenue and 19.9% profit growth guidance? Any revision would signal confidence shift or execution risk recognition. Margin recovery timing (still H2 inflection, or delayed?) is the critical signal.

Jubilant Pharmova's Q2 print is a hinge moment: the Street has priced in a recovery story anchored on SPECT batch releases and CMO utilization ramp in H2. If Q2 shows early signs of margin stabilization and SPECT is tracking, the 32% consensus upside holds and H2 guidance becomes live. If margins remain compressed and SPECT delays slip into H2, downside risk emerges quickly. The bulk of the ₹1,242 target assumes management's H2 inflection thesis is real; Q2 will be the first test of that credibility. Watch for EBITDA margin recovery, SPECT batch reality, and any revision to capital allocation or guidance.

Informational and educational content only. Not investment advice.